Nielsen E W, Gramstad S
Department of Anesthesiology, Nordland Hospital and University of Tromsø, Tromsø, Norway.
Acta Anaesthesiol Scand. 2006 Jan;50(1):120-2. doi: 10.1111/j.1399-6576.2005.00819.x.
Up to seven in every 1000 patients experience angioedema from angiotensin-converting enzyme (ACE) inhibitors, even after many years of use. In 2003, every 20th Norwegian used an ACE inhibitor.
A 61-year-old woman with chronic obstructive pulmonary disease and a past acute myocardial infarction had used 7.5 mg of ramipril daily for the past 7 years. She also used acetylsalicylic acid, simvastatin, theophylline and salmeterol. One night she woke up with edema of the tongue. On hospital arrival, 250 mg of hydrocortisone and 5 mg of dexchlorpheniramine were given intravenously (i.v.) and 0.3 mg of epinephrine was given subcutaneously (s.c.). The edema of the tongue progressed over the next 8 h and made the tongue protrude. Fiberscopy revealed glassy edema of the arytenoids. Inspiratory stridor was heard and the patient could not speak. She became increasingly uneasy and restless. Berinert complement 1 (C1) inhibitor concentrate (1500 units) was administered i.v. Over the following 20 min, stridor gradually subsided, the patient calmed and she was able to talk.
ACE inhibitor-provoked angioedema shares many clinical features with hereditary angioedema (HAE), including a limited effect of steroids, antihistamines and epinephrine. HAE, caused by excess bradykinin formation as a result of C1 inhibitor deficiency, usually has its laryngeal edema effectively reversed by C1 inhibitor in less than 0.5 h. Although patients experiencing ACE inhibitor-provoked angioedema have normal C1 inhibitor values, as in our patient, excess bradykinin is probably important as ACE breaks down bradykinin. It is unknown why ACE inhibitor-provoked angioedema appears in some and sometimes after many years of use.
We believe that C1 inhibitor was effective in reversing the ACE inhibitor-induced angioedema in our patient.
每1000名患者中多达7人会因血管紧张素转换酶(ACE)抑制剂出现血管性水肿,即便多年使用后仍会发生。2003年,每20个挪威人中就有1人使用ACE抑制剂。
一名61岁女性,患有慢性阻塞性肺疾病且有过急性心肌梗死病史,在过去7年中每日服用7.5毫克雷米普利。她还服用阿司匹林、辛伐他汀、茶碱和沙美特罗。一天夜里,她醒来时发现舌头水肿。入院后,静脉注射250毫克氢化可的松和5毫克右氯苯那敏,并皮下注射0.3毫克肾上腺素。接下来的8小时内,舌头水肿加重,致使舌头外伸。纤维喉镜检查显示杓状软骨呈玻璃样水肿。可闻及吸气性喘鸣,患者无法说话。她变得越来越不安和烦躁。静脉注射了1500单位的贝林奈特补体1(C1)抑制剂浓缩物。在接下来的20分钟内,喘鸣逐渐消退,患者平静下来并能够交谈。
ACE抑制剂诱发的血管性水肿与遗传性血管性水肿(HAE)有许多临床特征相同,包括类固醇、抗组胺药和肾上腺素的效果有限。HAE是由于C1抑制剂缺乏导致缓激肽生成过多引起的,通常C1抑制剂能在不到0.5小时内有效逆转其喉部水肿。尽管如我们的患者一样,经历ACE抑制剂诱发血管性水肿的患者C1抑制剂值正常,但过量的缓激肽可能很重要,因为ACE会分解缓激肽。尚不清楚为何ACE抑制剂诱发的血管性水肿会在一些患者中出现,且有时是在多年使用之后。
我们认为C1抑制剂有效地逆转了我们患者中ACE抑制剂诱发的血管性水肿。